FindTrial
Sign In

Study for the efficacy and safety of Conbercept in the treatment of NAION

Study for the efficacy and safety of Conbercept in the treatment of NAION

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000028874
Enrollment
Unknown
Registered
2020-01-05
Start date
2019-05-01
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-arteritic anterior ischemic optic neuropathy

Interventions

Experimental group:Conbercept intravitreal injection
Control group:Simulation of intravitreal injection

Sponsors

the First Medical Center of Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. NAION diagnosis; 2. Aged 40-65 years; 3. Best corrected vision 0.1-0.8.

Exclusion criteria

Exclusion criteria: 1. Other eye diseases; 2. Eye surgery; 3. Received other similar medication; 4. Poor systemic condition and serious cardiovascular and cerebrovascular diseases; 5. Pregnant women, etc.

Design outcomes

Primary

MeasureTime frame
BCVA;—

Countries

China

Contacts

Public ContactShihui Wei

the First Medical Center of Chinese PLA General Hospital

weishihui706@hotmail.com+86 13910079431

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026